Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample

Pharmacogenomics

Volumn 12, Issue 3, 2011, Pages 365-377

  Perroud, Nader ^a   Bondolfi, Guido ^a   Uher, Rudolf ^b   Gex Fabry, Marianne ^a   Aubry, Jean Michel ^a   Bertschy, Gilles ^c   Malafosse, Alain ^a   Kosel, Markus ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

5 HTR1B; ABCB1; antidepressant; depression; FKBP5; suicidal ideation

Indexed keywords

CATECHOL METHYLTRANSFERASE; CLOMIPRAMINE; CYTOCHROME P450 2D6; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 5; LIOTHYRONINE; LITHIUM; MULTIDRUG RESISTANCE PROTEIN 1; NEFAZODONE; PAROXETINE; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE; TRYPTOPHAN HYDROXYLASE 1; TRYPTOPHAN HYDROXYLASE 2; UNCLASSIFIED DRUG; VENLAFAXINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MONITORING; FEMALE; FK 506 BINDING PROTEIN 5 GENE; GENE; GENETIC ASSOCIATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MORNING DOSAGE; MULTIDRUG RESISTANCE PROTEIN 1 GENE; MUTATIONAL ANALYSIS; OUTPATIENT; PHARMACOGENOMICS; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK ASSESSMENT; SEROTONIN 1B RECEPTOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SUICIDAL BEHAVIOR; SUICIDAL IDEATION;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CLOMIPRAMINE; CYCLOHEXANOLS; DEPRESSIVE DISORDER; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PAROXETINE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, SEROTONIN, 5-HT1B; SEVERITY OF ILLNESS INDEX; SUICIDAL IDEATION; TACROLIMUS BINDING PROTEINS; TRIAZOLES; YOUNG ADULT;

EID: 79953234522     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.189     Document Type: Article

References (55)

1. Perroud N, Uher R, Marusic A et al.: Suicidal ideation during treatment of depression with esckalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP): a clinical trial. BMC Med. 7, 60 (2009).
2. Zisook S, Trivedi MH, Warden D et al.: Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study. Affect. Disord. 117(1-2), 63-73 (2009).
3. Pedis RH, Beasley CM Jr, Wines JD Jr et al: Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. Psychother. Psychosom. 76(1), 40-46 (2007). (Pubitemid 46005718)
4. Szanto K, Mulsant BH, Houck PR et al.: Emergence, persistence, and resolution of suicidal ideation during treatment of depression in old age. Affect. Disord. 98(1-2), 153-161 (2007). (Pubitemid 46055277)
5. Kraus JE, Horrigan JP, Carpenter DJ, Fong R, Barrett PS, Davies JT: Clinical features of patients with treatment-emergent suicidal behavior following initiation of paroxetine therapy. Affect. Disord. 120(1-3), 40-47 (2010).
6. Machado-Vieira R, Salvadore G, Luckenbaugh DA, Manji HK, Zarate CA: Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. Clin. Psychiatry 69(6), 946-958(2008). (Pubitemid 351944948)
7. Laje G, Paddock S, Manji H et al.: Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am. J. Psychiatry 164(10), 1530-1538 (2007). (Pubitemid 350069732)
8. Perils RH, Purcell S, FavaM .: Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch. Gen. Psychiatry 64(6), 689-697 (2007). (Pubitemid 46878669)
9. Perroud N,Aitchison KJ, Uher R, et al: Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacology 34(12), 2517-2528 (2009).
10. Brent D, Melhem N, Ferrell R, et al.: Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study Am. J. Psychiatry 167(2), 190-197 (2010).
11. Laje G, Allen AS, Akula N, Manji H, John Rush A, McMahon FJ: Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenet. Genomics 19(9), 666-674 (2009).
12. Perroud N, Uher R, Ng MY et al.: Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. Pharmacogenomics J. (2010) (Epub ahead of print).
13. Bondolfi G,AubryJM, GolazJ, Gex-FabryM, Gervasoni N, Bertschy G: A stepwise drug treatment algorithm to obtain complete remission in depression: a Geneva study. Swiss Med. Wkly 136(5-6), 78-85 (2006). (Pubitemid 43287243)
14. Sheehan DV, Lecrubier Y, Sheehan KH et al.: The Mini-International Neuropsychiatry: Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Clin. Psychiatry 59(Suppl. 20), 22-33; quiz 34-57 (1998). (Pubitemid 29001829)
15. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134, 382-389 (1979). (Pubitemid 9136500)
16. Rujescu D, Giegling I, Bondy B, Gietl A, Zill P, Moller HJ: Association of anger-related traits with SNPs in the TPHgene. Mol. Psychiatry 7(9), 1023-1029 (2002). (Pubitemid 35333060)
17. Manuck SB, Flory JD, Ferrell RE, Dent KM, Mann JJ, Muldoon MF: Aggression and anger-related traits associated with a polymorphism of the tryptophan hydroxylase gene. Biol. Psychiatry 45(5), 603-614 (1999). (Pubitemid 29147369)
18. Baud P, Perroud N, Courtet P et al.: Modulation of anger control in suicide attempters by TPH-1. Genes Brain Behav. 8(1), 97-100 (2009).
19. Jollant F, Buresi C, Guillaume S et al: The influence of four serotonin-related genes on decision-making in suicide attempters. Am. Med. Genet. BNeuropsychiatr. Genet. 144B(5), 615-624 (2007). (Pubitemid 47077145)
20. Paoloni-Giacobino A, Mouthon D, Lambercy C et al.: Identification and analysis of new sequence variants in the human tryptophan hydroxylase (TpH) gene. Mol. Psychiatry 5(1), 49-55 (2000). (Pubitemid 30088452)
21. Perroud N, Jaussent I, Guillaume S et al.: COMT but not serotonin-related genes modulates the influence of childhood abuse on anger traits. Genes Brain Behav. 9(2), 193-202 (2010).
22. Shih JC, Chen K: MAO-A and -B gene knock-out mice exhibit distinctly different behavior. Neurobiology (Bp) 7(2), 235-246 (1999). (Pubitemid 30353425)
23. Serretti A, Mandelli L, Giegling I et al.: HTR2C and HTRlA gene variants in German and Italian suicide attempters and completers. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B(3), 291-299 (2007). (Pubitemid 46642017)
24. Keltikangas-Jarvinen L, Puttonen S, Kivimaki M et al.: Serotonin receptor genes 5HT1A and 5HT2A modify the relation between childhood temperament and adulthood hostility. Genes Brain Behav. 7(1), 46-52 (2008).
25. Turecki G, Briere R, Dewar K et al.: Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am. J. Psychiatry 156(9), 1456-1458 (1999). (Pubitemid 29416550)
26. Et al.n B, Rousseva A, Roy I et al.: Lack of association between 5HT2A receptor gene haplotype, bipolar disorder and its clinical subtypes in a West European sample. Am. J. Med. Genet. B Neuropsychiatr. Genet. 129B(1), 29-33 (2004). (Pubitemid 38989063)
27. Zouk H, McGirr A, Lebel V, Benkelfat C, Rouleau G, Turecki G: The effect of genetic variation of the serotonin IB receptor gene on impulsive aggressive behavior and suicide. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B(8), 996-1002 (2007). (Pubitemid 350207772)
28. Rujescu D, Giegling I, Gietl A, Hartmann AM, Moller HJ: A functional single nucleotide polymorphism (V158M) in the COMT gene is associated with aggressive personality traits. Biol. Psychiatry 54(1), 34-39(2003). (Pubitemid 36776721)
29. Gex-Fabry M, Eap CB, Oneda B et al. CYP2D6 and ABCBl genetic variability: influence on paroxetine plasma level and therapeutic response. Ther. DrugMonit. 30(4), 474-482 (2008).
30. Rabe-Hesketh S, Skrondal A: Multilevel and Longitudinal Modeling using Stata. Press S (Ed.). Stata Press, TX, USA (2005).
31. Uher R, Maier W, Hauser J et al.: Differential efficacy of esckalopram and nortriptyline on dimensional measures of depression. Br. J. Psychiatry 194(3), 252-259 (2009).
32. Li J, Ji L: Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity 95(3), 221-227 (2005). (Pubitemid 43093236)
33. Nyholt DR: A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am. J. Hum. Genet. 74(4), 765-769 (2004). (Pubitemid 38420107)
34. Gauderman WJ: Sample size requirements for matched case-control studies of gene-environment interaction. Stat. Med. 21, 35-50 (2002). (Pubitemid 34065703)
35. Uher R, Farmer A, Maier W et al.: Measuring depression: comparison and integration of three scales in the GENDEP study. Psychol. Med. 38(2), 289-300 (2008). (Pubitemid 351156595)
36. SharmaA, Busnello JV, Ribeiro L et al.: Suicidalky scores during double-blind fluoxetine and desipramine treatment in Mexican Americans. Clin. Psychopharmacol. 27(1), 99-101 (2007).
37. Martinez C, Rietbrock S, Wise L et al.: Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 330(7488), 389 (2005).
38. Donovan S, ClaytonA, Beeharry M et al.: Deliberate self-harm and antidepressant drugs. Investigation of a possible link. Br. J. Psychiatry 177, 551-556 (2000). (Pubitemid 32005488)
39. Jick H, Kaye JA, Jick SS: Antidepressants and the risk of suicidal behaviors. JAMA 292(3), 338-343 (2004). (Pubitemid 38944257)
40. Hamilton MS, Opler LA: Akathisia, suicidality, and fluoxetine. Clin. Psychiatry 53(11), 401-406 (1992).
41. Teicher MH, Glod CA, Cole JO: Antidepressant drugs and the emergence of suicidal tendencies. DrugSaf 8(3), 186-212 (1993). (Pubitemid 23123065)
42. Gex-Fabry M, Haffen E, Paintaud G et al.: Population pharmacokinetics of clomipramine, desmethylclomipramine, and hydroxylated metabolites in patients with depression receiving chronic treatment: model evaluation. Ther. DrugMonit. 22(6), 701-711 (2000).
43. Seemuller F, Schennach-Wolff R, Obermeier M, Henkel V, Moller HJ, Riedel M: Does early improvement in major depression protect against treatment emergent suicidal ideation? Affect. Disord. 124(1-2), 183-186(2010).
44. WillourVL, Chen H, Toolan J et al.: Family-based association of FKBP5 in bipolar disorder. Mol. Psychiatry 14(3), 261-268 (2009).
45. Roy A, Gorodetsky E, Yuan Q, Goldman D, Enoch MA: Interaction of FKBP5, a stress-related gene, with childhood trauma increases the risk for attempting suicide. Neuropsychopharmacology 35 (8), 1674-1683 (2010).
46. IsingM, DeppingAM, SiebertzA et al.: Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. Eur. J. Neurosci. 28(2), 389-398 (2008).
47. Binder EB, Salyakina D, Lichtner P et al.: Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet. 36(12), 1319-1325 (2004). (Pubitemid 39577942)
48. Scammell JG, Denny WB, Valentine DL, Smith DF: Overexpression of the FK506-binding immunophilin FKBP51 is the common cause of glucocorticoid resistance in three new world primates. Gen. Comp. Endocrinol. 124(2), 152-165 (2001). (Pubitemid 33065587)
49. Mann JJ, Currier D: A review of prospective studies of biologic predictors of suicidal behavior in mood disorders. Arch. Suicide Res. 11(1), 3-16 (2007).
50. Cordon-Cardo C, O'Brien JP, Casals D et al.: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl Acad. Sci. USA 86(2), 695-698(1989). (Pubitemid 19037807)
51. Marzolini C, Paus E, Buclin T, Kim RB: Polymorphisms in human MDRl (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75(1), 13-33 (2004). (Pubitemid 38130115)
52. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR: ABCBl genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. PharmacogenomicsJ. 7(3), 154-179 (2007). (Pubitemid 46794925)
53. Bourin M, Chue P, Guillon Y: Paroxetine: a review. CNSDrugRev. 7(1), 25-47 (2001). (Pubitemid 32280682)
54. Gur E, Dremencov E, Van de Kar LD, Lerer B, Newman ME: Effects of chronically administered venlafaxine on 5-HT receptor activity in rat hippocampus and hypothalamus. Eur. J. Pharmacol. 436(1-2), 57-65 (2002). (Pubitemid 34142398)
55. Newman ME, Gur E, Dremencov E, Garcia F, Lerer B, Van de Kar LD: Chronic clomipramine alters presynaptic 5-HT(lB) and postsynaptic 5-HT(lA) receptor sensitivity in rat hypothalamus and hippocampus, respectively. Neuropharmacology 39(12), 2309-2317 (2000). (Pubitemid 30642773)